vs
ASP Isotopes Inc.（ASPI）与Gossamer Bio, Inc.（GOSS）财务数据对比。点击上方公司名可切换其他公司
ASP Isotopes Inc.的季度营收约是Gossamer Bio, Inc.的1.2倍（$16.7M vs $13.8M），ASP Isotopes Inc.同比增速更快（1295.7% vs 47.1%）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
Gossamer Bio是一家临床阶段生物制药企业，专注于发现、开发和商业化用于治疗免疫、炎症和肿瘤领域重症疾病的创新疗法，推进多条自研候选药物管线进入不同临床阶段，主要面向北美及全球其他地区的医疗市场。
ASPI vs GOSS — 直观对比
营收规模更大
ASPI
是对方的1.2倍
$13.8M
营收增速更快
ASPI
高出1248.6%
47.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $13.8M |
| 净利润 | — | $-47.2M |
| 毛利率 | 12.5% | — |
| 营业利润率 | — | -333.6% |
| 净利率 | — | -342.3% |
| 营收同比 | 1295.7% | 47.1% |
| 净利润同比 | -586.8% | -43.0% |
| 每股收益（稀释后） | — | $-0.21 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPIGOSS
| Q4 25 | $16.7M | $13.8M | ||
| Q3 25 | $4.9M | $13.3M | ||
| Q2 24 | — | $95.8M | ||
| Q1 24 | — | $0 | ||
| Q3 23 | — | $0 | ||
| Q2 23 | — | $0 |
净利润ASPIGOSS
| Q4 25 | — | $-47.2M | ||
| Q3 25 | $-12.9M | $-48.2M | ||
| Q2 24 | — | $49.2M | ||
| Q1 24 | — | $-41.9M | ||
| Q3 23 | — | $-40.0M | ||
| Q2 23 | — | $-42.5M |
毛利率ASPIGOSS
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
营业利润率ASPIGOSS
| Q4 25 | — | -333.6% | ||
| Q3 25 | -306.1% | -369.4% | ||
| Q2 24 | — | 54.3% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
净利率ASPIGOSS
| Q4 25 | — | -342.3% | ||
| Q3 25 | -263.7% | -362.7% | ||
| Q2 24 | — | 51.4% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
每股收益（稀释后）ASPIGOSS
| Q4 25 | — | $-0.21 | ||
| Q3 25 | $-0.15 | $-0.21 | ||
| Q2 24 | — | $0.22 | ||
| Q1 24 | — | $-0.19 | ||
| Q3 23 | — | $-0.21 | ||
| Q2 23 | — | $-0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $136.9M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $-122.8M |
| 总资产 | $498.0M | $172.2M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPIGOSS
| Q4 25 | $333.3M | $136.9M | ||
| Q3 25 | $113.9M | $180.2M | ||
| Q2 24 | — | $354.5M | ||
| Q1 24 | — | $244.4M | ||
| Q3 23 | — | $328.9M | ||
| Q2 23 | — | $162.1M |
总债务ASPIGOSS
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
股东权益ASPIGOSS
| Q4 25 | $204.2M | $-122.8M | ||
| Q3 25 | $74.1M | $-82.3M | ||
| Q2 24 | — | $81.5M | ||
| Q1 24 | — | $26.7M | ||
| Q3 23 | — | $104.6M | ||
| Q2 23 | — | $-62.8M |
总资产ASPIGOSS
| Q4 25 | $498.0M | $172.2M | ||
| Q3 25 | $225.9M | $208.8M | ||
| Q2 24 | — | $373.4M | ||
| Q1 24 | — | $259.4M | ||
| Q3 23 | — | $347.9M | ||
| Q2 23 | — | $181.7M |
负债/权益比ASPIGOSS
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-48.3M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | — |
| 自由现金流率自由现金流/营收 | -284.7% | — |
| 资本支出强度资本支出/营收 | 57.9% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASPIGOSS
| Q4 25 | $-37.8M | $-48.3M | ||
| Q3 25 | $-8.9M | $-36.2M | ||
| Q2 24 | — | $116.3M | ||
| Q1 24 | — | $-52.3M | ||
| Q3 23 | — | $-34.5M | ||
| Q2 23 | — | $-38.3M |
自由现金流ASPIGOSS
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
自由现金流率ASPIGOSS
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
资本支出强度ASPIGOSS
| Q4 25 | 57.9% | 0.0% | ||
| Q3 25 | 64.4% | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
现金转化率ASPIGOSS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 24 | — | 2.36× | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
